IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Effect of Adaptive Servo Ventilation (ASV) on Survival and Hospital Admissions in Heart Failure (ADVENT-HF)
This study is currently recruiting participants.
Verified October 2016 by Douglas Bradley, Toronto Rehabilitation Institute
Sponsor:
Toronto Rehabilitation Institute
Collaborators:
Canadian Institutes of Health Research (CIHR)
Philips Respironics
Information provided by (Responsible Party):
Douglas Bradley, Toronto Rehabilitation Institute
ClinicalTrials.gov Identifier:
NCT01128816
First received: April 26, 2010
Last updated: October 24, 2016
Last verified: October 2016
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Sleep Apnea (SA) is a disorder that causes pauses in breathing during sleep that expose the heart to oxygen deprivation. It is common in patients with heart failure (HF) where it is associated with increased risk of hospitalizations and death. It is not known however whether treating SA reduces these risks. This study is looking at whether a respiratory device known as Adaptive Servo Ventilation (ASV) can reduce the rate of cardiovascular hospitalizations and death in subjects with HF and SA. Study subjects will randomly receive either their regular medications OR their regular medications plus ASV. They will be followed for approximately 5 years and information relevant to their health will be collected and compared.
| Condition | Intervention | Phase |
|---|---|---|
| Sleep Apnea Heart Failure | Device: Adaptive Servo Ventilation | Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Multi-Centre, Randomized Study to Assess the Effects of Adaptive Servo Ventilation (ASV) on Survival and Frequency of Hospital Admissions in Patients With Heart Failure (HF) and Sleep Apnea (SA)-The ADVENT-HF Trial |
Resource links provided by NLM:
Further study details as provided by Douglas Bradley, Toronto Rehabilitation Institute:
Primary Outcome Measures:
- The time to the composite outcome of death or first CV hospital admission or new onset atrial fibrillation/flutter requiring anti-coagulation but not hospitalization or delivery of an appropriate shock from an ICD not resulting in hospitalization. [ Time Frame: The expected timeline is five years ]The study will end once 540 primary endpoints have occurred. Enrollment is expected to take 3 years with a minimum follow-up of 2 years thus the last patient is expected to complete the study by April 2015.
Secondary Outcome Measures:
- Time to death from any cause [ Time Frame: The expected timeline is 5 years ]The study will end once 540 primary endpoints have occurred.
- Number of cardiovascular hospitalizations per year of follow-up [ Time Frame: The minimum time of follow-up is expected to be 2 years. The maximum is expected to be 5 years ]
- Number of days alive not hospitalized [ Time Frame: Time from randomization to censoring (death, primary event or end of study) ]The number of days the patient is hospitalized are subtracted from the total number of days in the study from randomization. This number will be compared between the 2 groups.
- Changes in left ventricular function [ Time Frame: 6 months from randomization ]Changes in LV function will be assessed by echocardiography at 6 months post randomization
- Changes in plasma BNP levels [ Time Frame: 6 months from randomization ]Changes in plasma NT-proBNP levels will be assessed at baseline and at 6 months post randomization
- Cardiac resynchronization therapy or defibrillator implantations [ Time Frame: Average number of days until first cardiac resynchronization or first defibrillator implantation ]The average number of days from randomization to the first occurrence of CRT or defibrillator implantation will be calculated and compared between each treatment arm.
- Changes in 6 minute walk test distance [ Time Frame: 6 months from randomization ]Changes in the 6-minute walk distance between baseline and 6 months will be compared between the 2 groups
- Percentage of patients with changes in stages of heart failure and functional class [ Time Frame: Values obtained at study termination will be compared to those obtained at randomization ]New York Heart Association classification and AHA/ACC Stages of Heart Failure will be assessed at each visit.
- Changes in apnea/hypopnea index [ Time Frame: 1 month from randomization ]
- Changes in Quality of life assessments [ Time Frame: Assessments made at baseline, 1, 6, 12 and every 6 months thereafter ]Minnesota living with Heart Failure Questionnaire and Epworth Sleepiness Scale will be used. Scores will be compared between the 2 groups.
| Estimated Enrollment: | 860 |
| Study Start Date: | May 2010 |
| Estimated Study Completion Date: | July 2018 |
| Estimated Primary Completion Date: | July 2018 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
No Intervention: Standard HF therapy
Subjects will receive optimal standard therapy for heart failure conforming to national guidelines as determined by the referring cardiologist
|
|
|
Active Comparator: Standard therapy for HF + ASV
Subjects will receive treatment with Adaptive Servo Ventilation in addition to optimal standard therapy for heart failure conforming to national guidelines, as determined by the referring cardiologist
|
Device: Adaptive Servo Ventilation
BiPAP autoSV ADVANCED device worn nightly during sleep
Other Names:
|
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- American Heart Association Stage B-D Heart failure due to ischemic, idiopathic or hypertensive causes, present for at least 3 months
- Left Ventricular Ejection Fraction ≤ 45 %
- Optimal medical therapy for heart failure
- No change in active cardiac medications for 2 weeks prior to randomization, beta-blockers must be started 3 months prior to randomization
- Sleep apnea with an AHI ≥ 15. Subjects with obstructive sleep apnea must also have an Epworth Sleepiness Scale score of ≤ 10 and no or mild daytime sleepiness
- Written informed consent
Exclusion Criteria:
- Heart failure due to primary valvular heart disease
- Presence of moderate to severe mitral insufficiency due to intrinsic mitral valve disease
- Hypertrophic obstructive or restrictive or post partum cardiomyopathy
- Exercise capacity limited by class IV angina pectoris
- Acute MI, cardiac surgery, PCI, AICD, or CRT within 3 months of randomization
- Active myocarditis
- Planned AICD or CRT
- Presence of a left-ventricular assist device
- Transplanted heart or expected to receive a transplanted heart within the next 6 months
- Pregnancy
- Current use of ASV or CPAP or treated with any investigational therapy during the last 4 weeks (including approved therapies being used in unapproved indications)
- A clinical history that would interfere with the objectives of this study or that would in the investigator's opinion preclude safe conclusion of the study
- Any other medical, social, or geographical factor, which would make it unlikely that the patient will comply with the study procedures (e.g. alcohol abuse, lack of permanent residence, severe depression, disorientation, distant location, or history of non-compliance)
- Any contraindication to ASV therapy as detailed in the device provider manual
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01128816
Show 48 Study Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01128816
Contacts
| Contact: Novlette A Fraser | 416-597-3422 ext 7792 | Novlette.Fraser@uhn.ca |
Show 48 Study Locations
Sponsors and Collaborators
Toronto Rehabilitation Institute
Canadian Institutes of Health Research (CIHR)
Philips Respironics
Investigators
| Study Chair: | Douglas Bradley, M.D. | Toronto Rehabilitation Institute |
More Information
| Responsible Party: | Douglas Bradley, Study Chairman, Toronto Rehabilitation Institute |
| ClinicalTrials.gov Identifier: | NCT01128816 History of Changes |
| Other Study ID Numbers: |
ADVENT-HF trial |
| Study First Received: | April 26, 2010 |
| Last Updated: | October 24, 2016 |
Keywords provided by Douglas Bradley, Toronto Rehabilitation Institute:
|
obstructive sleep apnea central sleep apnea heart failure |
congestive heart failure adaptive servo ventilation ASV |
Additional relevant MeSH terms:
|
Heart Failure Apnea Sleep Apnea Syndromes Heart Diseases Cardiovascular Diseases Respiration Disorders Respiratory Tract Diseases |
Signs and Symptoms, Respiratory Signs and Symptoms Sleep Disorders, Intrinsic Dyssomnias Sleep Wake Disorders Nervous System Diseases |
ClinicalTrials.gov processed this record on August 16, 2017